# Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

> **NCT05650723** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Weill Medical College of Cornell University** · enrollment: 50 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **DRUG:** Zanubrutinib Pill
- **DRUG:** Venetoclax Pill
- **DRUG:** Obinutuzumab Injection

## Key facts

- **NCT ID:** NCT05650723
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-08
- **Primary completion:** 2027-03
- **Final completion:** 2027-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05650723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05650723, "Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05650723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*